These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 28875476)

  • 21. Pharmacological treatment of primary membranous nephropathy in 2016.
    van de Logt AE; Hofstra JM; Wetzels JF
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.
    Medrano AS; Escalante EJ; Cáceres CC; Pamplona IA; Allende MT; Terrades NR; Carmeno NV; Roldán EO; Agudelo KV; Vasquez JJ
    Biomarkers; 2015 Feb; 20(1):77-83. PubMed ID: 25519165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membranous Nephropathy: Core Curriculum 2021.
    Alsharhan L; Beck LH
    Am J Kidney Dis; 2021 Mar; 77(3):440-453. PubMed ID: 33487481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Membranous glomerulonephritis (MGN), ongoing studies].
    La Manna G; Baraldi O; Cunia V; Corradetti V; Aiello V; Busutti M; Gasperoni L; Spazzoli A; Comai G
    G Ital Nefrol; 2017 Sep; 34(5):113-118. PubMed ID: 28963832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances and prognosis in idiopathic membranous nephropathy.
    Segal PE; Choi MJ
    Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
    Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
    Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
    Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
    Seitz-Polski B; Payré C; Ambrosetti D; Albano L; Cassuto-Viguier E; Berguignat M; Jeribi A; Thouret MC; Bernard G; Benzaken S; Lambeau G; Esnault VL
    Nephrol Dial Transplant; 2014 Dec; 29(12):2334-42. PubMed ID: 25063424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology, diagnosis, and treatment of membranous nephropathy.
    Lutz J
    Nephrol Ther; 2021 Apr; 17S():S1-S10. PubMed ID: 33910688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of idiopathic membranous nephropathy.
    Hofstra JM; Fervenza FC; Wetzels JF
    Nat Rev Nephrol; 2013 Aug; 9(8):443-58. PubMed ID: 23820815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating antibodies to α-enolase and phospholipase A
    Kimura Y; Miura N; Debiec H; Morita H; Yamada H; Banno S; Ronco P; Imai H
    Clin Exp Nephrol; 2017 Feb; 21(1):117-126. PubMed ID: 26830547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Membranous nephropathy: Diagnosis, new insights in pathophysiology, and therapeutic approach].
    Dahan K
    Rev Med Interne; 2016 Oct; 37(10):674-679. PubMed ID: 27236434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
    Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
    Rojas-Rivera J; Fervenza FC; Ortiz A
    Drugs; 2022 Feb; 82(2):109-132. PubMed ID: 34932208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Membranous nephropathy: Pathophysiology and natural history].
    Seitz-Polski B; Lambeau G; Esnault V
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Membranous Nephropathy after MENTOR.
    Trivin-Avillach C; Beck LH
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):415-417. PubMed ID: 31740571
    [No Abstract]   [Full Text] [Related]  

  • 37. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary membranous nephropathy: comprehensive review and historical perspective.
    Keri KC; Blumenthal S; Kulkarni V; Beck L; Chongkrairatanakul T
    Postgrad Med J; 2019 Jan; 95(1119):23-31. PubMed ID: 30683678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?
    Stai S; Lioulios G; Christodoulou M; Papagianni A; Stangou M
    J Nephrol; 2023 Mar; 36(2):551-561. PubMed ID: 36450999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment.
    Lai WL; Yeh TH; Chen PM; Chan CK; Chiang WC; Chen YM; Wu KD; Tsai TJ
    J Formos Med Assoc; 2015 Feb; 114(2):102-11. PubMed ID: 25558821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.